Arvind Sreedharan, Senior Vice President, Business Operations
Mr. Sreedharan has more than 28 years of pharmaceutical and biotechnology experience in commercial roles of increasing responsibility at Ciba-Geigy, Abbott Laboratories, Ovation Pharmaceuticals, Lundbeck, Auspex Pharmaceuticals, and AveXis. He has significant experience in CNS disorders and multiple orphan diseases. Most recently, he served as Vice President, US Commercial Operations for AveXis, a gene therapy company acquired by Novartis for $8.7B. Mr. Sreedharan previously served as Vice President of Marketing at Auspex Pharmaceuticals, a biopharmaceutical company focused on hyperkinetic movement disorders and rare diseases, acquired by Teva Pharmaceutical for $3.5B. Prior to Auspex, he served as Director, Movement Disorders at Lundbeck, where he played an integral commercial role in the successful product launch and management of Xenazine®, the first and only FDA-approved drug for the treatment of chorea associated with Huntington’s disease. Throughout his career, Mr. Sreedharan has supported and partnered with numerous rare disease advocacy groups. He also served on the Huntington’s Disease Society of America board of trustees for six years. Mr. Sreedharan holds Bachelor of Arts degrees in biology and history from the University of North Carolina.